460 related articles for article (PubMed ID: 19536569)
1. Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings.
Hoefert S; Schmitz I; Tannapfel A; Eufinger H
Clin Oral Investig; 2010 Jun; 14(3):271-84. PubMed ID: 19536569
[TBL] [Abstract][Full Text] [Related]
2. Role of microcracks in the pathogenesis of bisphosphonate-related osteonecrosis of the jaw.
Kim JW; Landayan ME; Lee JY; Tatad JC; Kim SJ; Kim MR; Cha IH
Clin Oral Investig; 2016 Nov; 20(8):2251-2258. PubMed ID: 26795624
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates and osteonecrosis of the jaw: a retrospective study.
Murad OM; Arora S; Farag AF; Guber HA
Endocr Pract; 2007; 13(3):232-8. PubMed ID: 17599853
[TBL] [Abstract][Full Text] [Related]
4. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
5. Osteonecrosis of the jaw (ONJ) in cancer patients treated with Bisphosphonates: how the knowledge of a phenomenon can change its evolution.
La Verde N; Bareggi C; Garassino M; Borgonovo K; Sburlati P; Pedretti D; Bianchi C; Perrone S; Mihali D; Cobelli S; Mantica C; Rizzo A; Farina G
Support Care Cancer; 2008 Nov; 16(11):1311-5. PubMed ID: 18663482
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonate and nonbisphosphonate-associated osteonecrosis of the jaw: a review.
Almazrooa SA; Woo SB
J Am Dent Assoc; 2009 Jul; 140(7):864-75. PubMed ID: 19571050
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure.
Lo JC; O'Ryan FS; Gordon NP; Yang J; Hui RL; Martin D; Hutchinson M; Lathon PV; Sanchez G; Silver P; Chandra M; McCloskey CA; Staffa JA; Willy M; Selby JV; Go AS;
J Oral Maxillofac Surg; 2010 Feb; 68(2):243-53. PubMed ID: 19772941
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children?
Brown JJ; Ramalingam L; Zacharin MR
Clin Endocrinol (Oxf); 2008 Jun; 68(6):863-7. PubMed ID: 18221397
[TBL] [Abstract][Full Text] [Related]
9. [Osteonecrosis of the jaw].
Drozdzowska B
Endokrynol Pol; 2011; 62 Suppl 3():4-9. PubMed ID: 22161980
[TBL] [Abstract][Full Text] [Related]
10. [Bisphosphonate-associated osteonecrosis of the jaw].
Abu-Id MH; Açil Y; Gottschalk J; Kreusch T
Mund Kiefer Gesichtschir; 2006 Mar; 10(2):73-81. PubMed ID: 16456688
[TBL] [Abstract][Full Text] [Related]
11. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.
Mavrokokki T; Cheng A; Stein B; Goss A
J Oral Maxillofac Surg; 2007 Mar; 65(3):415-23. PubMed ID: 17307586
[TBL] [Abstract][Full Text] [Related]
12. Msx-1 is suppressed in bisphosphonate-exposed jaw bone analysis of bone turnover-related cell signalling after bisphosphonate treatment.
Wehrhan F; Hyckel P; Amann K; Ries J; Stockmann P; Schlegel K; Neukam F; Nkenke E
Oral Dis; 2011 May; 17(4):433-42. PubMed ID: 21366807
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene.
Lehrer S; Montazem A; Ramanathan L; Pessin-Minsley M; Pfail J; Stock RG; Kogan R
J Oral Maxillofac Surg; 2009 Jan; 67(1):159-61. PubMed ID: 19070762
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonate-related osteonecrosis of the jaws: an update on clinical, pathological and management aspects.
Ficarra G; Beninati F
Head Neck Pathol; 2007 Dec; 1(2):132-40. PubMed ID: 20614264
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies.
Boonyapakorn T; Schirmer I; Reichart PA; Sturm I; Massenkeil G
Oral Oncol; 2008 Sep; 44(9):857-69. PubMed ID: 18282788
[TBL] [Abstract][Full Text] [Related]
16. Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients.
Gabbert TI; Hoffmeister B; Felsenberg D
J Cancer Res Clin Oncol; 2015 Apr; 141(4):749-58. PubMed ID: 25319961
[TBL] [Abstract][Full Text] [Related]
17. Microbial biofilms in osteomyelitis of the jaw and osteonecrosis of the jaw secondary to bisphosphonate therapy.
Sedghizadeh PP; Kumar SK; Gorur A; Schaudinn C; Shuler CF; Costerton JW
J Am Dent Assoc; 2009 Oct; 140(10):1259-65. PubMed ID: 19797556
[TBL] [Abstract][Full Text] [Related]
18. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
[TBL] [Abstract][Full Text] [Related]
19. Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients.
Wutzl A; Eisenmenger G; Hoffmann M; Czerny C; Moser D; Pietschmann P; Ewers R; Baumann A
Wien Klin Wochenschr; 2006 Aug; 118(15-16):473-8. PubMed ID: 16957978
[TBL] [Abstract][Full Text] [Related]
20. Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw.
Miksad RA; Lai KC; Dodson TB; Woo SB; Treister NS; Akinyemi O; Bihrle M; Maytal G; August M; Gazelle GS; Swan JS
Oncologist; 2011; 16(1):121-32. PubMed ID: 21212433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
